LIMN
Liminatus Pharma, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
—
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
Liminatus Pharma, Inc.
Expected move
InputsNext report
Last report
—
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
News
−51.51%
shares held · 10 largest managers
No other changes.
No other changes.
| Manager | Value | % base | |
|---|---|---|---|
| Cygnus Capital | $36,000 | 34.56% | −5.90% |
| XTX Topco | $24,491 | 23.51% | new |
| Geodeindex-like | $15,282 | 14.67% | +17.52% |
| Citadel | $6,192 | 5.94% | −91.72% |
| Vanguardindex-like | $5,548 | 5.33% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| Cygnus Capital | $36,000 | 34.56% | −5.90% |
| XTX Topco | $24,491 | 23.51% | new |
| Geodeindex-like | $15,282 | 14.67% | +17.52% |
| Citadel | $6,192 | 5.94% | −91.72% |
| Vanguardindex-like | $5,548 | 5.33% | 0.00% |
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; no measured co-movers for Liminatus Pharma, Inc..
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; no measured co-movers for Liminatus Pharma, Inc..
Annual filing, covered
10-K parsed · Mar 31 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 31 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Liminatus Pharma, Inc.
2.94
+0.15 · +5.49%
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California.
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California.
Expected move
No implied move.